265 related articles for article (PubMed ID: 24297342)
1. SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.
Gu J; Han T; Ma RH; Zhu YL; Jia YN; Du JJ; Chen Y; Jiang XJ; Xie XD; Guo X
Int J Oncol; 2014 Feb; 44(2):481-90. PubMed ID: 24297342
[TBL] [Abstract][Full Text] [Related]
2. RASAL1 attenuates gastric carcinogenesis in nude mice by blocking RAS/ERK signaling.
Chen H; Zhao JY; Qian XC; Cheng ZY; Liu Y; Wang Z
Asian Pac J Cancer Prev; 2015; 16(3):1077-82. PubMed ID: 25735335
[TBL] [Abstract][Full Text] [Related]
3. Raf/MEK/ERK can regulate cellular levels of LC3B and SQSTM1/p62 at expression levels.
Kim JH; Hong SK; Wu PK; Richards AL; Jackson WT; Park JI
Exp Cell Res; 2014 Oct; 327(2):340-52. PubMed ID: 25128814
[TBL] [Abstract][Full Text] [Related]
4. Critical role of SHP2 (PTPN11) signaling in germinal center-derived lymphoma.
Jiang X; Guo H; Wu J; He Q; Li Y; Wang M; Pan H; Li W; Wang J; Wang Q; Shen J; Ke Y; Zhou R
Haematologica; 2014 Dec; 99(12):1834-45. PubMed ID: 25193962
[TBL] [Abstract][Full Text] [Related]
5. KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth.
Riverso M; Montagnani V; Stecca B
Oncogene; 2017 Jun; 36(23):3322-3333. PubMed ID: 28068326
[TBL] [Abstract][Full Text] [Related]
6. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of lipid phosphate phosphatase activity by VPC32183 suppresses the ability of diacylglycerol pyrophosphate to activate ERK(1/2) MAP kinases.
Violet PC; Billon-Denis E; Robin P
Biochim Biophys Acta; 2012 Nov; 1821(11):1394-405. PubMed ID: 22820196
[TBL] [Abstract][Full Text] [Related]
8. A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the ras-ERK pathway.
Wakasaki T; Masuda M; Niiro H; Jabbarzadeh-Tabrizi S; Noda K; Taniyama T; Komune S; Akashi K
Neoplasia; 2010 Oct; 12(10):789-96. PubMed ID: 20927317
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
10. The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival.
Hu Y; Mintz A; Shah SR; Quinones-Hinojosa A; Hsu W
Carcinogenesis; 2014 Jul; 35(7):1491-9. PubMed ID: 24445144
[TBL] [Abstract][Full Text] [Related]
11. Restoration of IRF1-dependent anticancer effects by MEK inhibition in human cancer cells.
AbuSara N; Razavi S; Derwish L; Komatsu Y; Licursi M; Hirasawa K
Cancer Lett; 2015 Feb; 357(2):575-81. PubMed ID: 25497010
[TBL] [Abstract][Full Text] [Related]
12. A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma.
Hu Z; Wang X; Fang H; Liu Y; Chen D; Zhang Q; Liu X; Wei D; Qu C; Wang S
Oncotarget; 2016 Feb; 7(5):5664-76. PubMed ID: 26673822
[TBL] [Abstract][Full Text] [Related]
13. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
Han T; Xiang DM; Sun W; Liu N; Sun HL; Wen W; Shen WF; Wang RY; Chen C; Wang X; Cheng Z; Li HY; Wu MC; Cong WM; Feng GS; Ding J; Wang HY
J Hepatol; 2015 Sep; 63(3):651-60. PubMed ID: 25865556
[TBL] [Abstract][Full Text] [Related]
14. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
15. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway.
Dance M; Montagner A; Salles JP; Yart A; Raynal P
Cell Signal; 2008 Mar; 20(3):453-9. PubMed ID: 17993263
[TBL] [Abstract][Full Text] [Related]
16. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
Dworakowska D; Wlodek E; Leontiou CA; Igreja S; Cakir M; Teng M; Prodromou N; Góth MI; Grozinsky-Glasberg S; Gueorguiev M; Kola B; Korbonits M; Grossman AB
Endocr Relat Cancer; 2009 Dec; 16(4):1329-38. PubMed ID: 19620247
[TBL] [Abstract][Full Text] [Related]
17. The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma.
Jiang C; Hu F; Tai Y; Du J; Mao B; Yuan Z; Wang Y; Wei L
J Cancer Res Clin Oncol; 2012 Apr; 138(4):637-46. PubMed ID: 22228034
[TBL] [Abstract][Full Text] [Related]
18. Cross-talk between endoplasmic reticulum (ER) stress and the MEK/ERK pathway potentiates apoptosis in human triple negative breast carcinoma cells: role of a dihydropyrimidone, nifetepimine.
Ghosh S; Adhikary A; Chakraborty S; Bhattacharjee P; Mazumder M; Putatunda S; Gorain M; Chakraborty A; Kundu GC; Das T; Sen PC
J Biol Chem; 2015 Feb; 290(7):3936-49. PubMed ID: 25527500
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
Wen-Sheng W
Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma.
Chen L; Shi Y; Jiang CY; Wei LX; Wang YL; Dai GH
Eur J Surg Oncol; 2011 Jun; 37(6):513-20. PubMed ID: 21324414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
